Sensus Q2 revenue down 21%, margins plunge as R&D, leasing spend rises; cash runway intact

Sensus Healthcare, Inc. (NASDAQ: SRTS) - quick read on what's happening inside the company and the income-statement takeaways.

Key facts & headline numbers
- Q2 2025 revenue: $7,315 thousand vs Q2 2024 $9,239 thousand (down 20.7%).
- Six months 2025 revenue: $15,659 thousand vs H1 2024 $19,902 thousand (down 21.1%).
- Q2 2025 gross profit: $2,903k (gross margin 39.7%) vs $5,423k (58.7%) in Q2 2024 - margin compression ~19 p.p..
- Six months gross profit: $7,256k (46.5%) vs $12,085k (60.8%) in prior year.
- Q2 2025 net loss: $(1,037)k; EPS (basic) $(0.06) vs Q2 2024 net income $1,612k, EPS $0.10.
- H1 2025 net loss: $(3,609)k; EPS (basic) $(0.22) vs H1 2024 net income $3,886k, EPS $0.24.
- Cash & cash equivalents: $22,162k at June 30, 2025 (roughly flat vs Dec 31, 2024).
- Accounts receivable: $12,622k (down $7.1m vs Dec 31, 2024). Inventories: $12,405k (up $2.3m vs Dec 31, 2024).
- Total assets: $58,852k; Total liabilities: $6,788k; Stockholders' equity: $52,064k.

What's happening inside
- Sales dropped materially vs prior year, driven by fewer unit sales to a large U.S. customer (company discloses one U.S. customer accounted for 56% of Q2 2025 revenue and 63% of H1 2025 revenue).
- Management is investing heavily: selling & marketing and R&D increased sharply (R&D +127.8% YTD; S&M +56.5% YTD) to support next‑generation products, clinical studies and lobbying for billing codes.
- Manufacturing relationship: company prepays manufacturer (paid $1.3m in Q2 2025); prepaid inventory $2.7m - production and supply chain remain central.
- Leasing business (Sensus Healthcare Services, LLC) provides recurring lease income (Q2 lease revenue total $358k); equipment-leasing builds a recurring revenue channel.
- Balance-sheet defensive items: $15m undrawn revolving credit facility with Comerica (no borrowings) and $22.2m cash give runway; facility covenants require $10m unencumbered in Comerica account.

Income statement - positives
- Company still generates meaningful gross profit: H1 gross margin 46.5% (despite drop from prior year).
- Cash from operations turned positive in H1 2025: net cash provided by operating activities $440k (improvement vs H1 2024 outflow).
- Investment in R&D and clinical efforts could support product roadmap and longer-term revenue diversification (next‑gen SRT systems and leasing expansion).
- Strong liquidity cushion: $22.2m cash + $15m available credit, and no outstanding draw on the credit line.

Income statement - negatives
- Revenues down ~21% Y/Y (Q2 and H1) - top-line decline large and concentrated to one customer.
- Gross margin deterioration: Q2 margin fell from 58.7% to 39.7% caused by lower unit sales plus higher servicing and placement program costs.
- Operating costs rising fast: G&A +31.3% YTD; S&M and R&D increases pushed operating expenses to $11.8m YTD (vs $7.2m prior YTD), producing an operating loss of $(4.6)m for H1 2025.
- Net loss of $(3.6)m YTD and negative EPS: dilution/antidilution dynamics exclude option shares due to losses.
- High customer concentration: one customer represented 56% of Q2 revenue and 78% of accounts receivable - persistent counterparty concentration risk.
- Legal/regulatory overhang: ongoing DOJ investigative history (since 2015) remains disclosed as contingency - potential execution and reputational risk.

Operational & liquidity notes to watch
- Accounts receivable fell $7.1m (helped cash flow) but remains concentrated. Monitor collections and payment terms with the large customer.
- Inventory increased to $12.4m - could be positive (preparing for demand) or negative (build of slow‑moving stock if sales don't recover).
- Prepayments to contract manufacturer ($2.7m prepaid inventory) highlight supplier exposure; continuity of manufacturing agreement is a covenant under the credit facility.
- Management believes current cash, maturing cash equivalents and available credit are sufficient for 12 months - but rising OpEx and uncertain sales trajectory keep funding risk present.

Bottom line
Sensus (NASDAQ: SRTS) has a solid liquidity base and is investing in product development and leasing to diversify revenue. But near-term performance is weak: revenue and margins have slipped materially, operating expenses surged and the business remains highly dependent on a single large customer. Key monitorables: sales recovery/diversification, margin stabilization, receivable concentration, and outcomes of regulatory/legal matters.

Data source: Sensus Healthcare, Inc. Form 10‑Q for the quarter ended June 30, 2025 (figures in thousands as reported).